Kornimate/medical-research-clean huggingface dataset:
tranexamic acid use in acute hip fractures

Conditions: Acute Hip Fractures

Summary: background: tranexamic acid (txa) has been used widely for the reduction of post operative blood loss for various orthopaedic procedures including but not limited to total hip arthroplasty and total knee arthroplasty. a recent multihospital meta-analysis conducted in 2013 showed that patients who received txa showed a significant reduction in post-operative transfusion (20.1% to 7.7%). the procedures the investigators will be evaluating are the intramedullary nail for intertrochanteric fracture and hip hemiarthroplasty. these procedures are similar to the total hip or knee replacement in that they can result in significant blood loss that requires a post operative transfusion. study purpose: to determine the efficacy of txa to decrease the rate of post-operative transfusion for acute hip fractures repaired with the following two methods, intramedullary nailing for intertrochanteric fracture and hemiarthroplasty. methods: the model for the study is a prospective randomized control trial. patients will be placed in one of two arms of the study after passing our inclusion criteria. the arms will be for either the intramedullary nailing for intertrochanteric fracture or for hemiarthroplasty. these two categories will be subdivided into those receiving txa and those not receiving txa. the patients in each category will have standard post-operative care and laboratory testing. the investigators will record the patients in either arm of the study, whether it be no txa or txa, who require post-operative transfusion within 1 week of the operation.

this is a prospective randomized control trial. patients scheduled for either intramedullary nailing for intertrochanteric fractures or for hemiarthroplasty will be selected for the study population. the proposed research is needed to bridge the gap between the efficacy of txa in elective, non-emergency procedures (such as total knee arthoplasty and total hip arthroplasty) and its efficacy in emergent acute hip fracture interventions. this study will use intravenous txa (1g pre-op and 1g post-op) to study its effect on both the reduction of blood loss during intramedullary nail for intertrochanteric fractures and hemiarthroplasty procedures, and the subsequent reduction in the rate of blood transfusion in this patient population. both study and control groups will have standard post-operative care and laboratory testing and will be followed for one year post-operatively to record adverse events.

Eligibility criteria:
inclusion criteria: * geriatric patients age 65 or older who require surgery for a low energy trauma hip fracture exclusion criteria: * prothrombotic state * cardiac stent within the past year with corresponding antiplatelet therapy * mechanical heart valves * deep vein thrombosis history * aortic stenosis * currently on coumadin * malignancy * kidney dialysis * non-english speaking patients * medications contraindicated with tranexamic acid.

Keywords: hemiarthroplasty intramedullary nail tranexamic acid transfusion
specific screw holes locating surgical guide and pre-bent plates

Conditions: Mandibular Fractures

Summary: the aim of the current study was to evaluate the accuracy of computer-guided mandibular fracture reduction versus the classical work flow

research question: does the use of screw holes locating surgical guide \& pre-bent plates osteosynthesis accurately reduce class iii mandibular fractures regarding segments integrity and occlusion more than the classical reduction and fixation? statement of the problem: mandibular fractures are the most frequently occurring fractures within the maxillofacial injuries. the evaluation, diagnosis, and management of these fractures remain challenging despite improved imaging technology and fixation techniques. depending on the type and location of the fractures, various open and closed surgical reduction techniques can be utilized. there are several critical and inherent limitations to the current ,standard approach of mandibular fracture reduction and fixation includes : (improper alignment of segments ,malocclusion ,nerve affections and related teeth roots injury). there is a possibility to overcome these limitations with the help of computer-guided surgery . the introduction of cad/cam software has provided surgeons with an opportunity to perform virtual manipulations of ct datasets preoperatively and production of corrected mandibular model for plate pre-bending and fabrication of plate locating surgical guide which provide accurate segment reduction and fixation with accurate post-operative occlusion and minimal post-operative complication . the aim of the current study was to evaluate the accuracy of computer-guided mandibular fracture reduction versus the conventional work flow rationale for conducting the research: through computer guided mandibular fracture reduction investigators can provide proper segment alignment with subsequent accurate post-operative occlusion in addition reduce intra-operative time , post-operative pain and edema

Eligibility criteria:
inclusion criteria: * patients with delayed and isolated mandibular class iii fracture needs open reduction and internal fixation. * patients with medical history that did not hinder plate placement (uncontrolled diabetes) and adequate proper oral hygiene. * both genders males and females will be included. exclusion criteria: * • general contraindications to surgery. * patients with fresh fractures (mobile segments). * patients with unfavourable nor comminuted fractures. * subjected to irradiation in the head and neck area less than 1 year before fixation. * untreated periodontitis. * poor oral hygiene and motivation. * uncontrolled diabetes. * pregnant or nursing. * substance abuse. * psychiatric problems or unrealistic expectations. * severe bruxism or clenching. * immunosuppressed or immunocompromised. * treated or under treatment with intravenous amino-bisphosphonates. * patients participating in other studies, if the present protocol could not be properly followed.

Keywords: class iii
hcu: can vhvs trained in iccm improve care for children

Conditions: Diarrhoea; Pneumonia; Malaria

Summary: this study will assess how the current vhv (vhv=chw, community health worker) scope can be expanded to include iccm and if such group interventions can provide improved access to treatment for children. in rural sw uganda, can iccm provided by lay volunteers, increase the proportion of children with diarrhoea receiving ors/zn, ari receiving anti-biotics, and fever/malaria receiving anti-malarials?


Eligibility criteria:
inclusion criteria: * women living in intervention and comparison villages * mother to at least one child under 59 months old exclusion criteria: -no living child

Keywords: antimalarials antibiotics ors zn village health volunteers integrated community case management
efficacy of voriconazole loaded spanlastics gel versus clotriamazole cream on treating vulvovaginal candidasis

Conditions: Breast Cancer

Summary: to investigate and compare the efficacy of voriconazole loaded spanlastics (vcz loaded sps) optimum gel formula (f2 vcz loaded sp gel) versus clotrimazole cream in treating candida albicans causing vulvovaginal candidiasis for different durations of 3 days and 5 days.

the current study will be prospective controlled randomized clinical trial. 28 female patients suffering from vulvovaginal candidiasis will be enrolled in the following 2 groups: gp 1 (test group): including 14 patients with vulvovaginal candidiasis albicans that will be randomized in the following subgroups: gp 1a: will be treated with f2 vcz loaded sp gel for 3 days. gp 1 b: will be treated with f2 vcz loaded sp gel for 5 days. gp 2 (control group): including 14 patients with vulvovaginal candidiasis albicans will be randomized in the following sub groups gp 2 a: will be treated with the clotrimazole cream available in the market for 3 days. gp 2 b: will be treated with the clotrimazole cream available in the market for 5 days. smears will be taken from the patients before starting the therapeutic protocol and after finishing it. compliance of the patients to the creams will be assesses

Eligibility criteria:
inclusion criteria: * female patients aging from 20 t0 40 years old suffering from vulvovaginal candidiasis caused by albicans species. exclusion criteria: * pregnant women, female suffering from vulvovaginal candidiasis caused by other species rather than c. albicans.
retrospective study in ffpe samples from younger patients with rhabdomyosarcoma

Conditions: Alveolar Childhood Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma; Recurrent Childhood Rhabdomyosarcoma

Summary: this retrospective study is looking into mechanisms of drug therapy resistance in ffpe samples in recurrent and refractory rhabdomyosarcoma (rms) in pediatric patients who have experienced lung recurrence. the study employs advanced techniques such as single-cell transcriptomics and spatial transcriptomics to gain a comprehensive understanding of these mechanisms.

this research seeks to enhance our understanding of drug resistance mechanisms in recurrent and refractory rms in pediatric patients, particularly in the context of lung recurrence. the utilization of cutting-edge techniques like single-cell transcriptomics and spatial transcriptomics allows for a more in-depth and comprehensive analysis of the molecular and spatial aspects of drug resistance in this challenging pediatric cancer.

Eligibility criteria:
inclusion criteria: 1. pediatric patients: participants in this study should be pediatric patients, typically defined as individuals aged from infancy to 18 years old, who have been diagnosed with recurrent and refractory rhabdomyosarcoma (rms). 2. lung recurrence: included patients must have a documented history of lung recurrence of rms as a specific clinical manifestation. 3. availability of ffpe samples: patients for whom formalin-fixed paraffin-embedded (ffpe) tissue samples are available for analysis are eligible for inclusion. exclusion criteria: 1. other histological types: patients with rms of histological subtypes other than those relevant to the study focus are excluded. 2. incomplete clinical data: patients with incomplete or insufficient clinical data necessary for the study's objectives may be excluded to ensure robust analysis and interpretation of results.
early migration in a high congruent rotating platform total knee prosthesis design

Conditions: Rheumatoid Arthritis

Summary: the aim of this study is to accurately assess the relationship between knee joint kinematics and migration of the tibial component of a high congruent, rotating platform total knee prosthesis by using fluoroscopy synchronised in time and space with a force plate, an external motion registration system and electromyography (emg).


Eligibility criteria:
inclusion criteria: * patient is diagnosed with osteoarthritis and requiring primary arthroplasty * patient is capable of giving informed consent and expressing a willingness to comply with this study * patient has no major deformities * the ability to perform a lunge and step-up motion without the help of bars or a cane. * no or slight pain during activity according to the knee society pain score (ewald, 1989; insall et al., 1989) exclusion criteria: * the patient is unable or unwilling to sign the informed consent specific to this study * the individual has a functional impairment of any other lower extremity joint besides the operated knee * patient has a flexion contracture of more than 15° * patient has a varus/valgus contracture of more than 15° * patients requiring revision arthroplasty * the patient does not understand the dutch or english language good enough to participate. * the use of walking aids * the inability to walk more than 500 meters

Keywords: knee joint arthroplasty replacement knee
keratoconus detection by ultrasound

Conditions: Keratoconus

Summary: keratoconus (kc) is a corneal disease which will in many cases ultimately require corneal transplantation to maintain vision. early detection, which is not possible with current technology, would allow early treatment and prevent severe damage to kc corneas inadvertently operated upon for correction of vision. the investigators' aim is to combine measurements of different properties of the cornea to develop means for early detection of kc.

keratoconus is the most common degenerative disease affecting the cornea. as keratoconus develops, the cornea thins and bulges. eventually, a corneal transplant may be needed to maintain vision. in its earliest stages, the disease is particularly difficult to detect. this is of great importance to the corneal refractive surgeon because surgical treatment of a keratoconic cornea will weaken it and greatly accelerate the occurrence of symptoms. early detection of keratoconus will benefit patients because of the recent development of methods for strengthening the corneal stroma and preventing disease progression. the investigators have developed a technique based on the use of high resolution ultrasound for imaging the cornea and measuring the thickness of its component layers, including the epithelium and the stroma. in early keratoconus, as the anterior stromal surface begins to bulge forward, the epithelium will thin above the apex of the bulge and thicken around it, to maintain a smooth anterior surface. the investigators have also developed methods for characterizing the elastic properties of the cornea by inducing and measuring surface displacements in response to a pulse of acoustic radiation force. the investigators' goal is to reduce the percentage of screened cases deemed keratoconus-suspect by at least a factor of two by allowing an unambiguous diagnosis of early keratoconus. this would provide two major benefits; (1) to be able to predict eyes with higher risk of developing ectasia after corneal refractive surgery, and (2) early diagnosis would allow earlier treatment of the condition with collagen crosslinking, preserving the cornea from disease progression.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of keratoconus (kc) or keratoconus-suspect * blood relation of person with kc * age-matched normal of kc subjects * ability to sit still in front of ultrasound unit and lie on exam table exclusion criteria: * other eye disease

Keywords: keratoconus keratoconus-suspect ultrasound exam acoustic radiation force ultrasound exam
an interventional study for patient with cancer pain to evaluate the efficacy and safety of oxynorm® compared to morphine sulfate through the iv continuous infusion.

Conditions: Cancer Pain

Summary: the purpose of this study is to compare of difference in nrs scores from baseline to the completion of treatment (5 days) in patients with administration of morphine sulfate versus oxycodone hydrochloride.

5days, multi-centers, randomization, open label, parallel, active comparator, phase 4 study.

Eligibility criteria:
inclusion criteria: 1. adult men and women aged 19 years or more 2. patients with cancerous pain who are hospitalized or scheduled for hospitalization at screening and not planned to be discharged during the study 3. patients with mean moderate to severe pain over the past 7 days at screening as verbally confirmed (nrs 4 or higher) 4. subjects who voluntarily signed the informed consent form for the study 5. subjects who are capable of understanding details of the study and verbal communication on pain intensity exclusion criteria: 1. patients who reached the narcotic analgesic dose corresponding to the followings for cancerous pain treatment immediately prior to screening (oral morphine dose 195mg/day, oral oxycodone dose 130mg/day, patch fentanyl dose 75μg/hour) 2. patients with a medical history of hypersensitivity to an ingredient of oxycodone hydrochloride or morphine sulfate or other narcotic analgesics 3. patients who have contraindications and cautions when study drugs administered.

Keywords: intravenous injection in cancer pain
impact of chlorhexidine cleansing on bacteria colonizing the umbilical cord of infants in bangladesh

Conditions: Infection

Summary: background: in developing countries, many babies are born at home and the umbilical cord commonly becomes infected during the first week after birth, and can be deadly. cleansing of the cord with a low-cost antiseptic like chlorhexidine may reduce the risk of these infections. little is known, however, about the frequency of chlorhexidine cleansing needed to impact upon the overall presence of bacteria on the stump, or regarding the changes in bacteria during the first week of life when most cord infections occur. objectives: we will describe the profile of bacteria colonizing the umbilical cord stump of infants in rural bangladesh and examine the role of topical chlorhexidine in altering colonization and progress of infection. we will compare the overall and bacteria-specific rate of colonization of the cord stump between infants receiving chlorhexidine cleansing of their cord through the first day or first week of life. we will also quantify the relationship between colonization of the cord stump with specific pathogens and the presence and severity of signs of umbilical cord infection (pus, redness, swelling) among these newborns. potential impact: more information is needed on the impact of single versus repeated applications of chlorhexidine to the cord stump, as the number of cleansing may substantially influence the feasibility of widespread scale-up in many populations. the data generated from this proposed study will guide the most appropriate design of this simple intervention and will help inform specific treatment protocols for effective management of infants with signs of umbilical cord infections.


Eligibility criteria:
inclusion criteria: * enrolled in parent chlorhexidine cleansing trial exclusion criteria: * not enrolled in parent trial * first visited after 48 hours of life

Keywords: chlorhexidine umbilical cord
study of t900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus

Conditions: Gastric Cancer; Esophageal Neoplasms

Summary: this is a clinical research study of t900607-sodium to determine if it is effective and safe in treating gastric cancer and adenocarcinoma of the esophagus. patients will be treated on a weekly basis with an intravenous injection of the study drug.


Eligibility criteria:
inclusion criteria * histologically or cytologically confirmed diagnosis of gastric cancer or adenocarcinoma of the esophagus * subjects must have received 1-2 regimens of prior chemotherapy * at least 18 years of age * bidimensionally measurable disease amenable to ct scanning. at least one lesion must be least 1 x 1 cm in size. * karnofsky performance status of at least 70% * estimated life expectancy of at least 12 weeks * females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive * subject must be able to comply with study procedures and follow-up examinations. * signed written informed consent * lab values (obtained ≤ 7 days prior to study enrollment): * anc at least 1.5x10e9/l, \* platelet count at least 100x10e9/l, * creatinine within 2 times upper limit of normal \* ast and alt within 5 times upper limit of normal * bilirubin within 1.5 times upper limit of normal * albumin great than 2.5 g/dl exclusion criteria * severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment * nyha class iii/iv cardiac disease, left ventricular ejection fraction (lvef) of \<50%, or acute anginal symptoms * patients who have received any investigational agent within 4 weeks of enrollment * patients who are pregnant or breast-feeding * history of prior malignancy other than gastric cancer or adenocarcinoma of the esophagus within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * history of central nervous system metastases or carcinomatous meningitis * major surgery within 4 weeks of enrollment

Keywords: adenocarcinoma of the esophagus
study to assess tolerability and safety and antibody response to g17dt in gastric cancer patients

Conditions: Gastric Cancer

Summary: open-label, multicenter study to assess 250µg/0.2ml g17dt injection at weeks 0, 2 and 6. at or after week 20 and up to and including week 44. subjects who raised antibodies to g17dt were given an additional dose of 125µg/0.1ml or 250µg/0.2ml g17dt between weeks 20-44 (study duration 52 weeks).


Eligibility criteria:
inclusion criteria: * patients who had had curative resection for histologically confirmed stage i, ii, or iii gastric carcinoma or carcinoma of the oesophagogastric junciton. * male or female patients over 18 years of age. * patients with a life expectancy of at least four months. * karnofsky index for performance status of \>70% * patients must have given written informed consent. exclusion criteria: * gastric or junctional surgery within three weeks of baseline (week 0) or gastric or junctional surgery anticipated in the study period. * history of other malignant disease within the previous five years, except non-melanomatous skin cancer or in situ carcinoma of the uterine cervix. * previous use (within the six weeks prior to the screening visit of the study), concomitant use, or anticipated use (up to week 16), of chemotherapy or immunotherapy. * previous use (within the six weeks prior to the screening visit of the study), concomitant use, or anticipated use (up to week 16), of radiotherapy or any other anti-cancer therapy. * previous use (within the four weeks prior to the screening visit of the study), concomitant use, or anticipated use (up to week 16), of immunosuppressants, including systemic corticosteroids. * known immunodeficiency. * females who were pregnant, planning to become pregnant or lactating. women, who in the opinion of the investigator were of child bearing potential, were to have a negative pregnancy test before study drug administration. * patients taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or up to week 16 during this study. * previous g17dt treatment. * haematological indicators: haemoglobin \<10.0g/dl neutrophils \< 2.0 x 109/l platelets \<100 x 109/l
efficacy and adverse effect of simvastatin compare to rosuvastatin in systemic lupus erythematosus (sle) patients with corticosteroid therapy and high low-density lipoprotein (ldl) cholesterol level

Conditions: Systemic Lupus Erythematosus; High LDL Cholesterol Level

Summary: early statin therapy in sle patients that have high cholesterol level and other atherosclerosis risk should reduce atherosclerosis and coronary artery events in later course of disease. by the way, statin is used in restricted groups of rheumatologists due to awareness of side effects; myositis and hepatitis, that are frequently found in sle patients more so than other groups of atherosclerosis patients and reporting data of autoimmune diseases that occur after statin use.


Eligibility criteria:
inclusion criteria: * sle patients that on prednisolone more than 30 mg/day * normal liver faction: ast and alt \< 80 mg/dl * normal muscle enzyme : cpk \< 100 u/l * ldl cholesterol level \> 100 mg/dl exclusion criteria: * patients that was treated with pulse methylprednisolone or corticosteroid equivalent to prednisolone \> 1mg/kg/day at screening. * statin allergy * on statin treatment before screening * on cyclosporine, antifugal (azole group), antibiotics (macrolide group), rifampicin, warfarin, phenytoin * pregnancy * abnormal liver function: ast or alt \> 80 mg/dl * abnormal muscle enzyme : cpk \> 300 u/l